INS and obesity due to melanocortin 4 receptor deficiency: Similarly, Timmers et al. (7) reported that 30 days of low-dose (∼1.5 mg/kg/d) resveratrol treatment in humans with obesity significantly reduced fasting plasma glucose and insulin levels.